The Society for Immunotherapy of Cancer (SITC) hosted the Summit on Intralesional Immunotherapy: Moving Beyond Oncolytic Viruses on Thursday, Sept. 19, from 11 a.m.–3:15 p.m. EDT. The free virtual summit was a public event that featured invited speakers, expert panel discussions, and attendee question and answer periods.
The SITC Summit on Intralesional Immunotherapy highlighted the latest translational and clinical research on intralesional immunotherapies and their impacts on the immune system, anti-tumor immunity, and the tumor microenvironment. Topics addressed at the summit included the current definitions of local immunotherapy, enhancing the effects of in situ vaccination, combining intralesional immunotherapies with other therapies, intralesional immunotherapy in the neoadjuvant setting, and high priority research areas for the field of intralesional immunotherapy.
This program provided an up-to-date overview of current and emerging intralesional immunotherapies and their potential clinical impact. Didactic presentations and panel discussions identified clinical and translational strategies, challenges, and opportunities in the field, highlighting intralesional immunotherapy as an important tool in the cancer immunotherapy toolbox.
View the summit recordings.